Developer docs
API playgroundTry for free, no card

Search company profiles

TendoNova

Full company profile

uuid0000xhi

Namestring
TendoNova
Legal namestring
TendoNova Corporation
Websiteurl
tendonova.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

TendoNova Corporation is a medical technology company founded in 2017 and headquartered in Atlanta, Georgia, that develops and manufactures the Ocelot, a handheld, battery-powered, FDA 510(k)-cleared micro-invasive device for office-based, ultrasound-guided percutaneous tenotomy to treat chronic tendinopathies. The system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter that mechanically fragments and debrides diseased tendon tissue, with an integrated cannula port that can be left in place for targeted delivery of biologic agents such as platelet-rich plasma after the procedure. Two issued U.S. patents (US 10,631,888 in April 2020 and US 11,357,530 in June 2022) protect the device, and manufacturing is performed in-house in Atlanta. The technology is positioned against ultrasonic tenotomy modalities such as Tenex, with the company's marketing materials specifically calling out the risk of burns from ultrasonic energy as a point of differentiation.

TendoNova sells to orthopedic surgeons, sports medicine physicians, physiatrists, and interventional MSK radiologists practicing in office-based and ambulatory surgical center settings, targeting indications including lateral/medial epicondylitis, plantar fasciitis, rotator cuff impingement, patellar tendinopathy, and Achilles, hamstring, gluteal, and quadriceps tendinopathy. Its revenue model is razor-and-blade: a one-time capital sale of the reusable drive unit and charging station to the practice, layered with recurring per-procedure sales of the sterile disposable cutting-tool assembly. Distribution combines a U.S. direct field-sales team led by a National Sales Director with channel partnerships, most notably AcCELLerated Biologics (signed March 2023), and an online "Find a Doctor" directory on tendonova.com that drives patient demand-side pull. Pricing is quote-based and not publicly disclosed, with clinicians directed to a 15-minute online demo and direct sales contact. A digital health companion (tablet plus mobile/device app) that captures device telemetry for procedure feedback is in development.

Commercial validation includes named accounts at Emory Sports Medicine, Mayo Clinic (Rochester), Dovetail Orthopedics, and Optim Orthopedics. Clinical study data referenced on the company site reports that 87% of patients treated for refractory tendinopathy reported positive results, with peer-reviewed support from Sharma & Thomas (2010), Strauser-Curtis et al. (2022), and Barnes et al. (2015). The company is backed by a 2017 founding team, NFL Players Inc. (2020), the Georgia Research Alliance (multiple grants), and a 2024 Preferred capital raise led by VentureSouth with CampbellKlein as co-investor. The company has 1-10 employees and no public revenue disclosure.

Short descriptiontext

TendoNova Corporation is an Atlanta-based medical device company that develops and manufactures the Ocelot, an FDA-cleared, handheld, battery-powered device for office-based ultrasound-guided tenotomy to treat chronic tendinopathies, sold to orthopedic and sports medicine physicians via direct sales and channel partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuwanee, United States
HQ citystring
Suwanee
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
percutaneous tenotomy devices, orthopedic medical devices, tendinopathy treatment systems, micro-invasive surgical tools, in-office orthopedic procedures
Industry1 code
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Capital hardware sales (reusable drive unit + charging station)
TypeHardware Sales
Description

One-time sale of the reusable handheld Ocelot drive unit and its charging station to physician practices, clinics, and ambulatory surgical centers. Represents the upfront capital expenditure by the customer.

tendonova.com
2Recurring sterile disposable unit sales
TypeUsage Based
Description

Recurring revenue from single-use sterile disposable units that house the cutting tool assembly; each procedure consumes one disposable, producing a razor/blade-style annuity on top of the capital install base.

tendonova.com
3Channel / distribution sales through partners
TypeTransaction Fee
Description

Indirect sales via distribution and channel partners (e.g., AcCELLerated Biologics) that carry the Ocelot alongside biologic adjacencies to expand reach to additional physician accounts.

tendonova.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Quote-based pricing for clinicians
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing obtained via demo booking and direct sales contact (sales@tendonova.com or 877-203-0161); no public price list, tier structure, or reimbursement codes disclosed.

tendonova.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ocelot®
Description

TendoNova's flagship line of FDA-cleared microinvasive, portable, handheld, battery-powered medical devices for percutaneous tenotomy and soft tissue fragmentation/debridement.

tendonova.com
+2 more records
Core offering1 text field

TendoNova develops and manufactures the Ocelot (also referenced as Ocelot Nano and Ocelot TSD 1000), an FDA 510(k)-cleared, handheld, battery-powered micro-invasive medical device for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue. The Ocelot system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter, and is sold to orthopedic and sports medicine physicians for in-office treatment of chronic tendinopathies. Recurring revenue is generated through single-use disposable units consumed per procedure, on top of the upfront capital sale of the drive unit.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 87% of patients treated for refractory tendinopathy reported positive results in a clinical study
+4 more records
Product overview1 text field

TendoNova offers a single core medical-device product — the Ocelot system (also referred to as Ocelot Nano and Ocelot TSD 1000) — supported by an optional digital-health add-on (a tablet companion with a mobile/device application) rather than a multi-module software platform. The Ocelot itself is an FDA-cleared, micro-invasive, handheld, battery-powered device used for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue in chronic tendinopathies, and is sold alongside a reusable drive unit, charging station, and disposable cutting-tool assembly. TendoNova's broader product roadmap is a series of instrumented micro-invasive tools designed to combine mechanical tenotomy with targeted delivery of biologic agents (e.g., platelet-rich plasma) and procedural feedback to clinicians.

Product and service2 records
1Ocelot (Ocelot Nano / Ocelot TSD 1000) micro-invasive tenotomy system
CategoryMedical device — percutaneous tenotomy system
Description

FDA-cleared, portable, handheld, battery-powered medical device for micro-invasive mechanical fragmentation and debridement of soft tissue via a rapidly oscillating stainless-steel Franseen cutter, used under ultrasound guidance for percutaneous tenotomy in chronic tendinopathies; sold to orthopedic, sports medicine, and office-based physicians.

2Ocelot sterile single-use disposable cutting-tool assembly
CategoryMedical device consumable / disposable accessory
Description

Single-use sterile disposable unit housing the cutting-tool assembly for the Ocelot system; one is consumed per procedure, enabling the razor/blade recurring revenue model and ensuring sterility.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-03-08
Description

Agreement signed March 8, 2023 to significantly expand the sales network for TendoNova's lead product, the Ocelot. AcCELLerated Biologics brings a decade of experience training and equipping physicians with biologic tools; the partnership gives the Ocelot access to those biologic customers and enables pairing of Ocelot tenotomy with biologic products. AcCELLerated Biologics CEO Steve Whyte commented publicly on the partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tenex Health
TypeDirect peer
Description

Tenex Health manufactures the established ultrasonic percutaneous tenotomy system that TendoNova explicitly positions the Ocelot against. It is the most direct competitor in office-based tenotomy for chronic tendinopathy and shares the same clinical call point and procedure workflow.

TypeDirect peer
Description

HydroCision's TenJet system performs minimally invasive tenotomy using a high-velocity saline jet. It competes head-to-head with the Ocelot in ultrasound-guided percutaneous tenotomy for tendinopathy and targets the same orthopedic and sports medicine physicians.

TypeBroad incumbent
Description

Arthrex is a private global leader in sports medicine and orthopedic surgical devices, including arthroscopic and percutaneous instruments. While it does not sell a direct tenotomy-only device, it covers the same surgeon call points and competes broadly for procedure share.

TypeBroad incumbent
Description

Smith+Nephew's Sports Medicine & ENT franchise sells arthroscopic, tendon repair, and minimally invasive orthopedic instruments. It is a broad incumbent whose portfolio overlaps with the procedural category TendoNova targets.

TypeBroad incumbent
Description

Stryker's orthopedic and surgical equipment portfolio (and prior acquisition of HyperBranch Medical Technology, where TendoNova director Jeffrey Clark was CEO) competes in the same MSK procedure space and represents a likely strategic acquirer profile for early-stage orthopedic device companies.

TypeBroad incumbent
Description

CONMED provides general surgery, orthopedic, and sports medicine devices including arthroscopic and electrosurgical instruments. It serves the same office-based and ASC clinician segment that the Ocelot targets for tenotomy procedures.

TypeBroad incumbent
Description

Integra LifeSciences offers orthopedic, sports medicine, and regenerative tissue technologies, including minimally invasive soft-tissue instruments. It is a broad incumbent with overlapping sports-medicine procedural adjacencies.

TypeEmerging player
Description

MiMedx sells regenerative tissue grafts and orthobiologics used in sports medicine and orthopedic surgery, complementing office-based tenotomy procedures. It is comparable via the biologics-plus-tenotomy workflow TendoNova promotes through its PRP cannula port.

TypeEmerging player
Description

Anika Therapeutics develops hyaluronic-acid-based and regenerative products for orthopedic and sports medicine applications. It targets the same MSK call points and overlaps thematically with TendoNova's tendon-pain focus.

TypeEmerging player
Description

Isto Biologics provides autologous bone-marrow concentrate and orthobiologic products used in sports medicine and orthopedic procedures. It is an emerging player in the same clinical workflow that the Ocelot serves, often co-administered with tenotomy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TendoNova

Orthopedic Medical Devicestendonova.com

TendoNova Corporation is an Atlanta-based medical device company that develops and manufactures the Ocelot, an FDA-cleared, handheld, battery-powered device for office-based ultrasound-guided tenotomy to treat chronic tendinopathies, sold to orthopedic and sports medicine physicians via direct sales and channel partners.

What TendoNova does

TendoNova Corporation is a medical technology company founded in 2017 and headquartered in Atlanta, Georgia, that develops and manufactures the Ocelot, a handheld, battery-powered, FDA 510(k)-cleared micro-invasive device for office-based, ultrasound-guided percutaneous tenotomy to treat chronic tendinopathies. The system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter that mechanically fragments and debrides diseased tendon tissue, with an integrated cannula port that can be left in place for targeted delivery of biologic agents such as platelet-rich plasma after the procedure. Two issued U.S. patents (US 10,631,888 in April 2020 and US 11,357,530 in June 2022) protect the device, and manufacturing is performed in-house in Atlanta. The technology is positioned against ultrasonic tenotomy modalities such as Tenex, with the company's marketing materials specifically calling out the risk of burns from ultrasonic energy as a point of differentiation.

TendoNova sells to orthopedic surgeons, sports medicine physicians, physiatrists, and interventional MSK radiologists practicing in office-based and ambulatory surgical center settings, targeting indications including lateral/medial epicondylitis, plantar fasciitis, rotator cuff impingement, patellar tendinopathy, and Achilles, hamstring, gluteal, and quadriceps tendinopathy. Its revenue model is razor-and-blade: a one-time capital sale of the reusable drive unit and charging station to the practice, layered with recurring per-procedure sales of the sterile disposable cutting-tool assembly. Distribution combines a U.S. direct field-sales team led by a National Sales Director with channel partnerships, most notably AcCELLerated Biologics (signed March 2023), and an online "Find a Doctor" directory on tendonova.com that drives patient demand-side pull. Pricing is quote-based and not publicly disclosed, with clinicians directed to a 15-minute online demo and direct sales contact. A digital health companion (tablet plus mobile/device app) that captures device telemetry for procedure feedback is in development.

Commercial validation includes named accounts at Emory Sports Medicine, Mayo Clinic (Rochester), Dovetail Orthopedics, and Optim Orthopedics. Clinical study data referenced on the company site reports that 87% of patients treated for refractory tendinopathy reported positive results, with peer-reviewed support from Sharma & Thomas (2010), Strauser-Curtis et al. (2022), and Barnes et al. (2015). The company is backed by a 2017 founding team, NFL Players Inc. (2020), the Georgia Research Alliance (multiple grants), and a 2024 Preferred capital raise led by VentureSouth with CampbellKlein as co-investor. The company has 1-10 employees and no public revenue disclosure.

TendoNova firmographics

Firmographics
Name
TendoNova
Legal name
TendoNova Corporation
Website
https://tendonova.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
TendoNova Corporation is an Atlanta-based medical device company that develops and manufactures the Ocelot, an FDA-cleared, handheld, battery-powered device for office-based ultrasound-guided tenotomy to treat chronic tendinopathies, sold to orthopedic and sports medicine physicians via direct sales and channel partners.
Ownership category
akta.pro rank

TendoNova industry classification

Industry
Product category
Orthopedic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Percutaneous tenotomy devices
  • Orthopedic medical devices
  • Tendinopathy treatment systems
  • Micro-invasive surgical tools
  • In-office orthopedic procedures

Where TendoNova is headquartered

Location

Headquarters

HQ city
Suwanee
HQ country
United States
HQ region
North America

Offices2 records

Markets served

TendoNova business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Capital hardware sales (reusable drive unit + charging station): One-time sale of the reusable handheld Ocelot drive unit and its charging station to physician practices, clinics, and ambulatory surgical centers. Represents the upfront capital expenditure by the customer.
  2. Recurring sterile disposable unit sales: Recurring revenue from single-use sterile disposable units that house the cutting tool assembly; each procedure consumes one disposable, producing a razor/blade-style annuity on top of the capital install base.
  3. Channel / distribution sales through partners: Indirect sales via distribution and channel partners (e.g., AcCELLerated Biologics) that carry the Ocelot alongside biologic adjacencies to expand reach to additional physician accounts.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for clinicians

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

TendoNova product offering

Product offering

Core offering

TendoNova develops and manufactures the Ocelot (also referenced as Ocelot Nano and Ocelot TSD 1000), an FDA 510(k)-cleared, handheld, battery-powered micro-invasive medical device for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue. The Ocelot system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter, and is sold to orthopedic and sports medicine physicians for in-office treatment of chronic tendinopathies. Recurring revenue is generated through single-use disposable units consumed per procedure, on top of the upfront capital sale of the drive unit.

Product overview

TendoNova offers a single core medical-device product — the Ocelot system (also referred to as Ocelot Nano and Ocelot TSD 1000) — supported by an optional digital-health add-on (a tablet companion with a mobile/device application) rather than a multi-module software platform. The Ocelot itself is an FDA-cleared, micro-invasive, handheld, battery-powered device used for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue in chronic tendinopathies, and is sold alongside a reusable drive unit, charging station, and disposable cutting-tool assembly. TendoNova's broader product roadmap is a series of instrumented micro-invasive tools designed to combine mechanical tenotomy with targeted delivery of biologic agents (e.g., platelet-rich plasma) and procedural feedback to clinicians.

Differentiator

Problem solved

Functional benefit

Brands

  • Ocelot®: TendoNova's flagship line of FDA-cleared microinvasive, portable, handheld, battery-powered medical devices for percutaneous tenotomy and soft tissue fragmentation/debridement.
  • Ocelot® Nano
  • Ocelot™ TSD 1000

Products and services

  • Ocelot (Ocelot Nano / Ocelot TSD 1000) micro-invasive tenotomy system FDA-cleared, portable, handheld, battery-powered medical device for micro-invasive mechanical fragmentation and debridement of soft tissue via a rapidly oscillating stainless-steel Franseen cutter, used under ultrasound guidance for percutaneous tenotomy in chronic tendinopathies; sold to orthopedic, sports medicine, and office-based physicians.
  • Ocelot sterile single-use disposable cutting-tool assembly Single-use sterile disposable unit housing the cutting-tool assembly for the Ocelot system; one is consumed per procedure, enabling the razor/blade recurring revenue model and ensuring sterility.

Quantifiable outcome

  • 87% of patients treated for refractory tendinopathy reported positive results in a clinical study
  • +4 more outcomes

Companies that use TendoNova

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

TendoNova technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

TendoNova partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AcCELLerated BiologicsflagshipChannel Partner/ Reseller/ Distributor · 8 March 2023Agreement signed March 8, 2023 to significantly expand the sales network for TendoNova's lead product, the Ocelot. AcCELLerated Biologics brings a decade of experience training and equipping physicians with biologic tools; the partnership gives the Ocelot access to those biologic customers and enables pairing of Ocelot tenotomy with biologic products. AcCELLerated Biologics CEO Steve Whyte commented publicly on the partnership.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

TendoNova competitors and assessment

Company assessment

Direct peers

  • Tenex Health: Tenex Health manufactures the established ultrasonic percutaneous tenotomy system that TendoNova explicitly positions the Ocelot against. It is the most direct competitor in office-based tenotomy for chronic tendinopathy and shares the same clinical call point and procedure workflow.
  • HydroCision (TenJet): HydroCision's TenJet system performs minimally invasive tenotomy using a high-velocity saline jet. It competes head-to-head with the Ocelot in ultrasound-guided percutaneous tenotomy for tendinopathy and targets the same orthopedic and sports medicine physicians.

Broad incumbents

  • Arthrex: Arthrex is a private global leader in sports medicine and orthopedic surgical devices, including arthroscopic and percutaneous instruments. While it does not sell a direct tenotomy-only device, it covers the same surgeon call points and competes broadly for procedure share.
  • Smith+Nephew: Smith+Nephew's Sports Medicine & ENT franchise sells arthroscopic, tendon repair, and minimally invasive orthopedic instruments. It is a broad incumbent whose portfolio overlaps with the procedural category TendoNova targets.
  • Stryker: Stryker's orthopedic and surgical equipment portfolio (and prior acquisition of HyperBranch Medical Technology, where TendoNova director Jeffrey Clark was CEO) competes in the same MSK procedure space and represents a likely strategic acquirer profile for early-stage orthopedic device companies.
  • CONMED: CONMED provides general surgery, orthopedic, and sports medicine devices including arthroscopic and electrosurgical instruments. It serves the same office-based and ASC clinician segment that the Ocelot targets for tenotomy procedures.
  • Integra LifeSciences: Integra LifeSciences offers orthopedic, sports medicine, and regenerative tissue technologies, including minimally invasive soft-tissue instruments. It is a broad incumbent with overlapping sports-medicine procedural adjacencies.

Emerging players

  • MiMedx: MiMedx sells regenerative tissue grafts and orthobiologics used in sports medicine and orthopedic surgery, complementing office-based tenotomy procedures. It is comparable via the biologics-plus-tenotomy workflow TendoNova promotes through its PRP cannula port.
  • Anika Therapeutics: Anika Therapeutics develops hyaluronic-acid-based and regenerative products for orthopedic and sports medicine applications. It targets the same MSK call points and overlaps thematically with TendoNova's tendon-pain focus.
  • Isto Biologics: Isto Biologics provides autologous bone-marrow concentrate and orthobiologic products used in sports medicine and orthopedic procedures. It is an emerging player in the same clinical workflow that the Ocelot serves, often co-administered with tenotomy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

TendoNova social profiles

Digital presence

TendoNova compliance and trust

Trust signal

Compliance5 records

TendoNova financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TendoNova leadership team

Management profile

Number of profiles

Profiles13 records

TendoNova funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TendoNova M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TendoNova

What does TendoNova do?

TendoNova develops and manufactures the Ocelot (also referenced as Ocelot Nano and Ocelot TSD 1000), an FDA 510(k)-cleared, handheld, battery-powered micro-invasive medical device for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue. The Ocelot system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter, and is sold to orthopedic and sports medicine physicians for in-office treatment of chronic tendinopathies. Recurring revenue is generated through single-use disposable units consumed per procedure, on top of the upfront capital sale of the drive unit.

Is TendoNova a public or private company?

TendoNova is a private company. It is classified as venture growth investor backed and is currently operating.

When was TendoNova founded?

TendoNova was founded in 2017. It employs 11 to 50 people.

Where is TendoNova based?

TendoNova is headquartered in Suwanee, United States, in the North America region.

How does TendoNova make money?

Three revenue lines are on record. Capital hardware sales (reusable drive unit + charging station) is the primary driver. The others are recurring sterile disposable unit sales and channel / distribution sales through partners.

Who are TendoNova's main competitors?

Direct peers on record are Tenex Health and HydroCision (TenJet). Broad incumbents are Arthrex, Smith+Nephew, Stryker, CONMED and Integra LifeSciences. Emerging players are MiMedx, Anika Therapeutics and Isto Biologics.

Does TendoNova have an API?

No public API is recorded for TendoNova.

What industry is TendoNova in?

TendoNova's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DTendoNova Corp filed a Form D with the SEC on May 29, 2024, for an exempt securities offering under Rule 506(b). The company reported raising $761,999 of its total offering amount from six investors as of the filing date. This regulatory filing discloses details regarding the equity offering and executive officers involved in the transaction.SecSEC FORM DTendoNova Corp has filed a Notice of Exempt Offering of Securities with the SEC, indicating an offering amount of $1,100,000, with $626,999 already sold. The company aims to raise funds through equity securities and intends for this offering to last less than one year.SecSEC FORM DTendoNova Corp filed a Form D with the SEC for an exempt securities offering under Rule 506(b), with a total offering amount of $1,100,000. The company has sold $601,999 of the securities to four investors as of the filing date in March 2024. This regulatory filing discloses the financial parameters and investor count for the biotechnology firm's current capital raise.GlobeNewswireTendoNova Inks Partnership with AcCELLerated BiologicsTendoNova announced a partnership with AcCELLerated Biologics to expand the sales network for its Ocelot device, which performs mechanical fragmentation or debridement of tendons. The Ocelot is FDA-cleared and manufactured in Atlanta, and the partnership aims to combine biologics with the device for tendinopathy treatment.SecSEC FORM DTendoNova Corp filed a Form D with the SEC for an exempt securities offering under Rule 506(b) on August 12, 2022. The company is raising a total of $700,000, having already sold $160,000 to four investors. This filing discloses the initial public notice of the private capital raise.PR NewswireTendoNova wins FDA Clearance for Its New Microinvasive Ocelot Surgical ToolTendoNova has received FDA 510(k) clearance for its new Ocelot surgical tool, designed for the fragmentation or debridement of soft tissue. The Ocelot system offers a cost-effective alternative to existing tools and is intended to assist in treating chronic tendon pain, a condition affecting over 30 million people in the U.S. The tool is expected to be available to physicians in the second half of 2022.SecSEC FORM DTendoNova Corp, a Delaware corporation incorporated in 2017 and based in Norcross, Georgia, filed a Form D notice of an exempt offering of equity pooled investment fund interests under Rule 506(b). The $2 million offering has sold $170,000, leaving $1.83 million remaining, with three investors including non-accredited investors. No sales commissions or finder's fees were disclosed.GlobeNewswireTendoNova Receives GRA Phase III Commercialization FundingTendoNova Corporation has been selected for the Georgia Research Alliance (GRA) Phase III commercialization program, receiving up to $250,000 in debt funding. The company plans to launch its Ocelot™ system in early 2022 and currently has a pending FDA application for the device. This funding supports TendoNova's efforts to commercialize its microinvasive orthopedic procedures.NH Business ReviewEx-TendoNova CEO sues company over termination paymentRoy Wallen, former CEO of TendoNova, sued the company in U.S. District Court, alleging he was never paid wages, expenses, or restricted stock options. He claims he worked over a full week and raised nearly $1 million in capital, while the company says he was a consultant and has already provided shares. The company has not yet replied to the suit.BusinessnhmagazineBusiness NH MagazineThe John Flatley Company announced the winners of its 2018 Flatley Challenge, awarding TendoNova and XoGo first place in their respective categories along with cash prizes and office space. The ceremony is scheduled for February 20 at the Nashua Technology Park, where Mayor Jim Donchess will speak.